CY1110474T1 - Nsaid σκευασματα τα οποια περιλαμβανουν ελαια λεκιθινης για προστασια της γαστρεντερικης οδου και παροχη αυξημενης θεραπευτικης δραστικοτητας - Google Patents

Nsaid σκευασματα τα οποια περιλαμβανουν ελαια λεκιθινης για προστασια της γαστρεντερικης οδου και παροχη αυξημενης θεραπευτικης δραστικοτητας

Info

Publication number
CY1110474T1
CY1110474T1 CY20091100168T CY091100168T CY1110474T1 CY 1110474 T1 CY1110474 T1 CY 1110474T1 CY 20091100168 T CY20091100168 T CY 20091100168T CY 091100168 T CY091100168 T CY 091100168T CY 1110474 T1 CY1110474 T1 CY 1110474T1
Authority
CY
Cyprus
Prior art keywords
increased therapeutic
gastrestrian
nsaid
olive
road
Prior art date
Application number
CY20091100168T
Other languages
Greek (el)
English (en)
Inventor
Lenard Lichtenberger
Original Assignee
The Board Of Regents Of The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Regents Of The University Of Texas System filed Critical The Board Of Regents Of The University Of Texas System
Publication of CY1110474T1 publication Critical patent/CY1110474T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dispersion Chemistry (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CY20091100168T 2000-12-19 2009-02-17 Nsaid σκευασματα τα οποια περιλαμβανουν ελαια λεκιθινης για προστασια της γαστρεντερικης οδου και παροχη αυξημενης θεραπευτικης δραστικοτητας CY1110474T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25671100P 2000-12-19 2000-12-19
EP01273758A EP1343529B1 (en) 2000-12-19 2001-12-19 Nsaid formulations comprising lecithin oils for protecting the gastrointestinal tract and providing enhanced therapeutic activity

Publications (1)

Publication Number Publication Date
CY1110474T1 true CY1110474T1 (el) 2015-04-29

Family

ID=22973287

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100168T CY1110474T1 (el) 2000-12-19 2009-02-17 Nsaid σκευασματα τα οποια περιλαμβανουν ελαια λεκιθινης για προστασια της γαστρεντερικης οδου και παροχη αυξημενης θεραπευτικης δραστικοτητας

Country Status (17)

Country Link
EP (1) EP1343529B1 (enExample)
JP (2) JP4958381B2 (enExample)
KR (1) KR100884493B1 (enExample)
CN (2) CN1543358A (enExample)
AT (1) ATE414542T1 (enExample)
AU (1) AU2001297778B2 (enExample)
BR (1) BR0116380A (enExample)
CA (1) CA2431606C (enExample)
CY (1) CY1110474T1 (enExample)
DE (1) DE60136647D1 (enExample)
DK (1) DK1343529T3 (enExample)
ES (1) ES2317873T3 (enExample)
IL (2) IL156361A0 (enExample)
MX (1) MXPA03005550A (enExample)
PT (1) PT1343529E (enExample)
SI (1) SI1343529T1 (enExample)
WO (1) WO2002085414A2 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2534241C (en) 2003-07-31 2012-05-29 The Board Of Regents Of The University Of Texas System Compositions and methods for treating, preventing and/or ameliorating cancers, the onset of cancers or the symptoms of cancers
US20050176809A1 (en) * 2004-02-05 2005-08-11 Rodlen Laboratories, Inc. Method and compositions for treatment of painful disorders
WO2005084683A1 (fr) * 2004-03-03 2005-09-15 MARTINS, José, Araujo Composition a base de lecithine vegetale, ex. de soja, vitamines du complexe b et d'acide acetylsalicylique, et son utilisation pour la fabrication d'un medicament pour le traitement des maladies neuro-degeneratives
AU2005295874B2 (en) * 2004-10-12 2011-01-27 The Board Of Regents Of The University Of Texas System Purified phospholipid-non-steroidal anti-inflammatory drug associated compositions and methods for preparing and using same
GB0517673D0 (en) * 2005-08-31 2005-10-05 Astrazeneca Ab Formulation
CA2626579A1 (en) * 2005-10-25 2007-05-03 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
MX2009000658A (es) 2006-07-19 2009-01-30 Univ Texas Preparaciones de fosfolipidos y componentes farmaceuticos que contienen acido 5-amino salicilico para el tratamiento de una enfermedad inflamatoria del intestino delgado.
US20110008396A1 (en) * 2007-09-20 2011-01-13 Rutgers, The Sate University Of New Jersey Compositions and methods for treating cardiovascular conditions
GB2477590A (en) * 2010-02-05 2011-08-10 Biocopea Ltd A non-steroidal anti-inflammatory drug (NSAID) formulation comprising a lipid carrier
DK2629779T3 (en) * 2010-10-22 2017-10-02 Dr Reddy's Laboratories Sa Use of stock stable viscous phospholipid depot for wound treatment
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9737500B2 (en) 2010-10-29 2017-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US8895537B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating cardiovascular diseases
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
JP2014507429A (ja) * 2011-02-04 2014-03-27 バイオコピア リミテッド 心血管疾患の治療のための組成物および方法
WO2013022410A2 (en) 2011-08-08 2013-02-14 Mahmut Bilgic Production method for effervescent formulations comprising dexketoprofen
CN103957888B (zh) 2011-09-29 2017-11-21 PLx 制药公司 用于将药物沿胃肠道靶向释放的pH依赖性载体、其组合物及其制备和应用
EP2999487A1 (en) * 2013-05-23 2016-03-30 Neurosn, Inc. Diagnosing and treating alzheimer's disease using annexins with labeled with a radionuclide
US9446056B2 (en) * 2014-02-11 2016-09-20 Dr. Reddy's Laboratories Ltd. Parenteral compositions of celecoxib
CN103908454B (zh) * 2014-04-17 2016-08-24 兆科药业（广州）有限公司 一种药物组合物及其制备方法和应用
WO2016094617A1 (en) * 2014-12-11 2016-06-16 Phosphorex, Inc. Aqueous topical drug formulation with controlled release and increased stability
CN104739843A (zh) * 2015-04-15 2015-07-01 郭志标 一种用于治疗口腔溃疡的药物组合物
AU2019231699B2 (en) * 2018-03-07 2023-03-09 Andrew Xian Chen Aqueous formulations for insoluble drugs
CN108542909B (zh) * 2018-03-30 2020-07-07 浙江海昶生物医药技术有限公司 一种阿司匹林磷脂固化组合物、其制备方法及药物制剂
JP7229012B2 (ja) * 2018-12-25 2023-02-27 小林製薬株式会社 内服用医薬組成物
WO2021195319A1 (en) 2020-03-26 2021-09-30 Plx Opco Inc. PHARMACEUTICAL CARRIERS CAPABLE OF pH DEPENDENT RECONSTITUTION AND- METHODS FOR MAKING AND USING SAME
CN120643509B (zh) * 2025-08-18 2025-12-05 杭州市滨江区浙医二院经血管植入器械研究院 血管内长效留存的油相药物溶液及液体灌注球囊传递方式

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60208910A (ja) * 1984-03-31 1985-10-21 Green Cross Corp:The 水難溶性薬物・リン脂質複合体の製造方法
US5154930A (en) * 1987-03-05 1992-10-13 The Liposome Company, Inc. Pharmacological agent-lipid solution preparation
US5091188A (en) 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
DK0625898T3 (da) * 1992-02-12 1996-06-03 Janssen Cilag S P A Liposom-piroxicamformuleringer
ATE218872T1 (de) * 1995-01-27 2002-06-15 Univ Texas Verfahren zur erhöhung der therapeutischen wirkung von nsaids und dazu verwendbare zwitterionische phospholipidhaltige zusammensetungen
US5955451A (en) * 1995-05-12 1999-09-21 The University Of Texas System Board Of Regents Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein

Also Published As

Publication number Publication date
ATE414542T1 (de) 2008-12-15
JP4958381B2 (ja) 2012-06-20
EP1343529B1 (en) 2008-11-19
PT1343529E (pt) 2009-02-27
DK1343529T3 (da) 2009-03-16
CA2431606C (en) 2011-07-19
AU2001297778C1 (en) 2002-11-05
SI1343529T1 (sl) 2009-04-30
JP2005506303A (ja) 2005-03-03
CN102258457A (zh) 2011-11-30
IL156361A0 (en) 2004-01-04
MXPA03005550A (es) 2004-05-14
JP2010031044A (ja) 2010-02-12
ES2317873T3 (es) 2009-05-01
IL156361A (en) 2011-04-28
CN102258457B (zh) 2015-07-01
EP1343529A2 (en) 2003-09-17
KR100884493B1 (ko) 2009-02-18
HK1161107A1 (en) 2012-08-24
WO2002085414A2 (en) 2002-10-31
KR20030072565A (ko) 2003-09-15
WO2002085414A3 (en) 2003-05-08
AU2001297778B2 (en) 2007-05-31
DE60136647D1 (de) 2009-01-02
CN1543358A (zh) 2004-11-03
BR0116380A (pt) 2005-04-05
CA2431606A1 (en) 2002-10-31

Similar Documents

Publication Publication Date Title
CY1110474T1 (el) Nsaid σκευασματα τα οποια περιλαμβανουν ελαια λεκιθινης για προστασια της γαστρεντερικης οδου και παροχη αυξημενης θεραπευτικης δραστικοτητας
CY1119148T1 (el) Φαρμακευτικες συνθεσεις και συναφεις μεθοδοι χορηγησης
DE69637866D1 (de) Methoden zur Erhöhung der Wirksamkeit von nicht-steroidalen antientzündlichen Arzneien und dazu verwendbare Zusammensetzungen enthaltend zwitterionische Phospholipide
AR036448A1 (es) Composiciones farmaceuticas de conjugados droga insulina-oligomeros, y metodos para tratar las enfermedades con los mismos
DK1411900T3 (da) Farmaceutiske sammensætninger til den koordinerede frigørelse af NSAIDs
ES2930524T3 (es) Complejos que contienen estroncio de administración tópica para el tratamiento del dolor, el prurito y la inflamación
CY1105202T1 (el) Διασπειρομενες φαρμακευτικες συνθεσεις
NO20045656L (no) Oftalmologisk anvendelse av roflumilast for behandlingen av oyesykdommer
HN2000000050A (es) Sal mutua de amlodipino y atorvastatina
TR199800631A2 (xx) Ecza form�lasyonu.
PE20050822A1 (es) Derivados de florfenicol con mejor solubilidad en agua
UY27969A1 (es) Formulaciones que comprenden un compuesto de indolinona
DE60325887D1 (de) Pharmazeutische zusammensetzungen zurbehandlung von augenerkrankungen
BR9915610A (pt) Preparações farmacêuticas combinadas
DK1251846T3 (da) C4-Carbonattaxaner
DE60042831D1 (de) Pharmazeutisch aktive sulfonylaminosäurederivate
CY1106055T1 (el) Τυποποιηση των υποκατεστημενων βενζιμιδαζολων
DE60220666D1 (de) Steigerung der wirksamkeit von wirkstoffen durch micellare zubereitung mit retinolderivaten
ES2503540T3 (es) Composición farmacéutica que combina un agente antiinflamatorio no esteroideo y un agente anticonvulsionante
DE69621773D1 (de) Verfahren zur erhöhung der therapeutischen wirkung von nsaids und dazu verwendbare zwitterionische phospholipidhaltige zusammensetungen
UY30029A1 (es) Derivados de piperidina, sus sales farmacéuticamente aceptables, composiciones farmacéuticas conteniéndolos y aplicaciones
ES2182504T3 (es) Bifenilsulfonilcianamidas, procedimiento para su preparacion y su utilizacion como medicamento.
NO20061515L (no) Anvendelse av okskarbazepin for behandling av diabetisk neurpatisk smerte og forbedring av sovn
US20050042241A1 (en) Dr. Bob's Arthritis Cream
EA200101157A1 (ru) 14β-H-СТЕРОЛЫ, СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И ПРИМЕНЕНИЕ ЭТИХ ПРОИЗВОДНЫХ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ, РЕГУЛИРУЮЩИХ МЕЙОЗ